Literature DB >> 12716407

Serotonin stimulates hypothalamic mRNA expression and local release of neurohypophysial peptides.

H Jørgensen1, A Kjaer, U Knigge, M Møller, J Warberg.   

Abstract

The neurotransmitter serotonin (5-HT) stimulates the secretion of vasopressin and oxytocin, and 5-HT is involved in the mediation of the vasopressin and oxytocin response to stress. In male Wistar rats, we investigated the 5-HT receptors involved in the 5-HT-induced increase of mRNA expression of vasopressin and oxytocin in the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON). The 5-HT precursor, 5-hydroxytryptophan, injected in combination with the 5-HT reuptake inhibitor, fluoxetine, increased oxytocin mRNA expression in the PVN, and the concentration of vasopressin and oxytocin in plasma, whereas mRNA in the SON was not affected. Intracerebroventricular infusion of 5-HT agonists selective for the 5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C receptor increased oxytocin mRNA in the SON and PVN. Infusion of agonists selective for the 5-HT2A + 2C receptor increased vasopressin mRNA in the PVN, whereas none of the 5-HT agonists affected vasopressin mRNA in the SON. All the 5-HT agonists infused increased peripheral oxytocin concentration and vasopressin was increased by stimulation of the 5-HT2A, 5-HT2C and 5-HT3 receptor. Intracerebroventricular infusion of 100 nmol 5-HT increased the extracellular hypothalamic concentration of vasopressin as measured by microdialysis in the PVN. To evaluate the involvement of hypothalamic-pituitary system in the 5-hydroxytryptophan and fluoxetine-induced vasopressin secretion, rats were immunoneutralized with a specific anti-corticotropin-releasing hormone antiserum. This treatment reduced plasma vasopressin and oxytocin responses. We conclude that stimulation with 5-hydroxytryptophan or 5-HT agonists increases mRNA expression of oxytocin in the PVN and the SON via stimulation of at least 5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C receptors. Vasopressin mRNA in the PVN was increased only via the 5-HT2 receptor, whereas vasopressin mRNA in the SON does not seem to be affected by 5-HT stimulation. Corticotropin-releasing hormone appears to be partly involved in the mediation of 5-HT induced vasopressin and oxytocin secretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716407     DOI: 10.1046/j.1365-2826.2003.01032.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  13 in total

1.  Proteomic Analysis of the Human Anterior Pituitary Gland.

Authors:  Soujanya D Yelamanchi; Ankur Tyagi; Varshasnata Mohanty; Pinaki Dutta; Márta Korbonits; Sandip Chavan; Jayshree Advani; Anil K Madugundu; Gourav Dey; Keshava K Datta; M Rajyalakshmi; Nandini A Sahasrabuddhe; Abhishek Chaturvedi; Amit Kumar; Apabrita Ayan Das; Dhiman Ghosh; Gajendra M Jogdand; Haritha H Nair; Keshav Saini; Manoj Panchal; Mansi Ashwinsinh Sarvaiya; Soundappan S Mohanraj; Nabonita Sengupta; Priti Saxena; Pradeep Annamalai Subramani; Pradeep Kumar; Rakhil Akkali; Saraswatipura Vishwabrahmachar Reshma; Ramachandran Sarojini Santhosh; Sangita Rastogi; Sudarshan Kumar; Susanta Kumar Ghosh; Vamshi Krishna Irlapati; Anand Srinivasan; Bishan Das Radotra; Premendu P Mathur; G William Wong; Parthasarathy Satishchandra; Aditi Chatterjee; Harsha Gowda; Anil Bhansali; Akhilesh Pandey; Susarla K Shankar; Anita Mahadevan; T S Keshava Prasad
Journal:  OMICS       Date:  2018-12

2.  Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands.

Authors:  David H Overstreet; Darin J Knapp; Robert A Angel; Montserrat Navarro; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2006-05-19       Impact factor: 4.530

3.  Tryptophan Hydroxylase 2 Knockout Male Rats Exhibit a Strengthened Oxytocin System, Are Aggressive, and Are Less Anxious.

Authors:  Xianzong Meng; Joanes Grandjean; Giulia Sbrini; Pieter Schipper; Nita Hofwijks; Jesse Stoop; Francesca Calabrese; Judith Homberg
Journal:  ACS Chem Neurosci       Date:  2022-10-05       Impact factor: 5.780

4.  A single prolonged stress paradigm produces enduring impairments in social bonding in monogamous prairie voles.

Authors:  Aki Arai; Yu Hirota; Naoki Miyase; Shiori Miyata; Larry J Young; Yoji Osako; Kazunari Yuri; Shinichi Mitsui
Journal:  Behav Brain Res       Date:  2016-08-10       Impact factor: 3.332

5.  Impact of gestational cocaine treatment or prenatal cocaine exposure on early postpartum oxytocin mRNA levels and receptor binding in the rat.

Authors:  M S McMurray; E T Cox; T M Jarrett; S K Williams; C H Walker; J M Johns
Journal:  Neuropeptides       Date:  2008-06-24       Impact factor: 3.286

6.  Flibanserin-Stimulated Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets.

Authors:  Alexander K Converse; Yves Aubert; Kelly A Allers; Bernd Sommer; David H Abbott
Journal:  J Sex Med       Date:  2015-12-04       Impact factor: 3.802

Review 7.  The BTBR T+ tf/J mouse model for autism spectrum disorders-in search of biomarkers.

Authors:  Ksenia Z Meyza; Erwin B Defensor; Ashley L Jensen; Michael J Corley; Brandon L Pearson; Roger L H Pobbe; Valerie J Bolivar; D Caroline Blanchard; Robert J Blanchard
Journal:  Behav Brain Res       Date:  2012-08-09       Impact factor: 3.332

8.  Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder.

Authors:  Charlotte Keating; Tye Dawood; David A Barton; Gavin W Lambert; Alan J Tilbrook
Journal:  BMC Psychiatry       Date:  2013-04-29       Impact factor: 3.630

9.  Combined norepinephrine/serotonergic reuptake inhibition: effects on maternal behavior, aggression, and oxytocin in the rat.

Authors:  Elizabeth Thomas Cox; Thomas Merryfield Jarrett; Matthew Stephen McMurray; Kevin Greenhill; Vivian E Hofler; Sarah Kaye Williams; Paul Wayland Joyner; Christopher L Middleton; Cheryl H Walker; Josephine M Johns
Journal:  Front Psychiatry       Date:  2011-06-08       Impact factor: 4.157

10.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.